Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis

09/16/2021 | 06:28am EDT

By Dave Sebastian

AbbVie Inc. said it has submitted applications seeking approval for upadacitinib, a candidate for treating adults with moderately to severely active ulcerative colitis, to the U.S. Food and Drug Administration and the European Medicines Agency.

The company on Thursday said the applications are supported from two Phase 3 induction studies and one maintenance study. More patients treated with the drug candidate reached the primary endpoint of clinical remission and all secondary endpoints compared with a placebo, it said.

Ulcerative colitis is a type of inflammatory bowel disease of the large intestine. Symptoms include rectal bleeding, abdominal pain and bloody diarrhea.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

09-16-21 0828ET

All news about ABBVIE INC.
09:17aABBVIE : Says its Psoriatic Arthritis Drug Risankizumab Recommended by CHMP for Treatment ..
MT
07:04aAbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis
DJ
10/14PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..
DJ
10/14ABBVIE INC. : Ex-dividend day for
FA
10/12ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..
AQ
10/11Health Care Stocks Sliding in Late Monday Trading
MT
10/11Health Care Stocks Drifting Monday as Biotechs Climb
MT
10/08ABBVIE : Upadacitinib (RINVOQ) Met Primary and Most Ranked Secondary Endpoints in Phase 3 ..
AQ
10/08ABBVIE : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 S..
AQ
10/07ABBVIE : Gets Health Canada's Approval for Rinvoq to Treat Atopic Dermatitis
MT
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 204 M - -
Net income 2021 12 473 M - -
Net Debt 2021 66 426 M - -
P/E ratio 2021 14,9x
Yield 2021 4,69%
Capitalization 192 B 192 B -
EV / Sales 2021 4,61x
EV / Sales 2022 4,13x
Nbr of Employees 48 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 108,91 $
Average target price 125,48 $
Spread / Average Target 15,2%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.1.64%192 463
JOHNSON & JOHNSON1.73%421 487
ROCHE HOLDING AG15.58%336 383
PFIZER, INC.12.52%233 631
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.19%214 579